Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients

@article{Clifton2017ResultsOA,
  title={Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients},
  author={G. Travis Clifton and Jennifer K Litton and RN KarenArrington and Sathibalan Ponniah and Nuhad K. Ibrahim and Victor A Gall and DO PhDGheathAlatrash and George Earl Peoples and PhD FACS Elizabeth A. Mittendorf},
  journal={Annals of Surgical Oncology},
  year={2017},
  volume={24},
  pages={2161-2167}
}
CD8+ T cell-eliciting vaccines are being investigated in breast cancer patients. Preclinical data showed that trastuzumab increases the susceptibility of tumor cells to lysis by vaccine-generated CD8+ T cells, suggesting potential benefit of a combination immunotherapy strategy. The current trial was undertaken to demonstrate the safety of this approach. This study was designed as a dose-escalation trial enrolling clinically disease-free, human leukocyte antigen A2+ or A3+ , human epidermal… CONTINUE READING